GYRE
Gyre Therapeutics Inc (GYRE)
Healthcare • NASDAQ • $7.47+5.66%
- Symbol
- GYRE
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $7.47
- Daily Change
- +5.66%
- Market Cap
- $724.55M
- Trailing P/E
- N/A
- Forward P/E
- 124.50
- 52W High
- $11.78
- 52W Low
- $6.57
- Analyst Target
- $18.67
- Dividend Yield
- N/A
- Beta
- 5.28
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-o…
Company websiteResearch GYRE on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.